ACS chemical neuroscience molecule spotlight on BMS-708163

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

BMS-708163 is a novel, sulfonamide containing γ-secretase inhibitor from Bristol-Myers Squibb Co. currently in Phase II clinical trials for the treatment of Alzheimer's disease (AD).

Original languageEnglish (US)
Pages (from-to)149-150
Number of pages2
JournalACS Chemical Neuroscience
Volume3
Issue number3
DOIs
StatePublished - Mar 21 2012

Fingerprint

Amyloid Precursor Protein Secretases
Phase II Clinical Trials
Sulfonamides
Neurosciences
Alzheimer Disease
Molecules
BMS 708163

Keywords

  • Alzheimer's disease
  • GSI
  • amyloid hypothesis
  • gamma-secretase inhibitors

ASJC Scopus subject areas

  • Biochemistry
  • Physiology
  • Cognitive Neuroscience
  • Cell Biology

Cite this

ACS chemical neuroscience molecule spotlight on BMS-708163. / Hopkins, Corey R.

In: ACS Chemical Neuroscience, Vol. 3, No. 3, 21.03.2012, p. 149-150.

Research output: Contribution to journalReview article

@article{4867608c7baa460ba7d9003efa93ad46,
title = "ACS chemical neuroscience molecule spotlight on BMS-708163",
abstract = "BMS-708163 is a novel, sulfonamide containing γ-secretase inhibitor from Bristol-Myers Squibb Co. currently in Phase II clinical trials for the treatment of Alzheimer's disease (AD).",
keywords = "Alzheimer's disease, GSI, amyloid hypothesis, gamma-secretase inhibitors",
author = "Hopkins, {Corey R.}",
year = "2012",
month = "3",
day = "21",
doi = "10.1021/cn3000179",
language = "English (US)",
volume = "3",
pages = "149--150",
journal = "ACS Chemical Neuroscience",
issn = "1948-7193",
publisher = "American Chemical Society",
number = "3",

}

TY - JOUR

T1 - ACS chemical neuroscience molecule spotlight on BMS-708163

AU - Hopkins, Corey R.

PY - 2012/3/21

Y1 - 2012/3/21

N2 - BMS-708163 is a novel, sulfonamide containing γ-secretase inhibitor from Bristol-Myers Squibb Co. currently in Phase II clinical trials for the treatment of Alzheimer's disease (AD).

AB - BMS-708163 is a novel, sulfonamide containing γ-secretase inhibitor from Bristol-Myers Squibb Co. currently in Phase II clinical trials for the treatment of Alzheimer's disease (AD).

KW - Alzheimer's disease

KW - GSI

KW - amyloid hypothesis

KW - gamma-secretase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=84858760430&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84858760430&partnerID=8YFLogxK

U2 - 10.1021/cn3000179

DO - 10.1021/cn3000179

M3 - Review article

C2 - 22860183

AN - SCOPUS:84858760430

VL - 3

SP - 149

EP - 150

JO - ACS Chemical Neuroscience

JF - ACS Chemical Neuroscience

SN - 1948-7193

IS - 3

ER -